ProKidney Corp. (PROK) Stock Price & Analysis
ProKidney Corp. (PROK) — MoonshotScore 13/100 (Weak band), calculated Nov 18, 2026. Price $1.04 (-1.89%), as of the Nov 20, 2026 trading session; market cap $415M.
Educational signal · not a buy or sell recommendation · How to read this
ProKidney Corp. · PROK · NASDAQ
ProKidney Corp. is a clinical-stage biotechnology company focused on developing cellular therapy candidates for kidney disease. Their lead candidate, Renal Autologous Cell Therapy (REACT), is currently in Phase III development.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · ProKidney (PROK)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and stalling growth, and it’s expensive on top — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Bubble; Growth Durability: Shrinking; Momentum: Slipping.
- quarterly revenue $217,000 (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 0 of the last 4 reports
- Altman Z -4.51 · Piotroski F 1
Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 13 | Weak | |
| 13 | Weak | |
| 13 | Weak | |
| 13 | Weak | |
| 13 | Weak | |
| 13 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.04 | |
| Change on the day | -1.89% | |
| Market capitalisation | $415M | — |
| Shares traded on the day | 1.90M |
Price & events
Other perspectives
Council score for ProKidney (PROK): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 21, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 21, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is ProKidney (PROK), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. ProKidney Corp. (PROK) is listed on NASDAQ. It employs 231 people. In Q3 FY2025 it reported revenue of $217,000 and net income of -$16M. The market values it at $415M.
What do the latest results show for ProKidney (PROK)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $217,000. Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $217,000 | -$16M | -$0.12 (diluted) |
| Q4 FY2025 | $225,000 | -$19M | — |
| Q1 FY2026 | $226,000 | -$20M | -$0.14 (diluted) |
| Q2 FY2026 | $150,000 | -$28M | -$0.15 (diluted) |
What are the financial strengths and risks for ProKidney (PROK)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth. The distress and quality screens read Altman Z -4.51 · Piotroski F 1. Trailing ratios: ROE -73.4% · ROA -42.9% · current ratio 5.04.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -4.51 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-73.4%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
How does ProKidney compare with its peers?
Short answer
ProKidney's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $8.76 Nov 20, 2026 | $521M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $40.09 Nov 20, 2026 | $755M | 88 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $9.19 Nov 20, 2026 | $540M | 68 5-pillar Nov 18, 2026 | |
| $19.19 Nov 20, 2026 | $1.18B | 66 5-pillar Nov 18, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 | |
| $21.73 Nov 20, 2026 | $3.68B | 62 5-pillar Nov 18, 2026 | |
| ProKidney (PROK) — this page | $1.04 | $415M | 13 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held PROK in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported PROK in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about ProKidney (PROK)?
Common Questions About PROK
These answers are editorial: 1 of these 9 answers is drawn from the PROK research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for PROK?
PROK carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. ProKidney Corp. is a clinical-stage biotechnology company focused on developing cellular therapy candidates for kidney disease.
Is PROK a good stock to buy?
Stock Expert AI does not rate PROK buy, sell or hold. ProKidney Corp. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PROK stock price today?
The last price recorded for ProKidney Corp. (PROK), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about PROK stock?
Analyst coverage of ProKidney Corp. is still emerging, given its clinical-stage nature. Key valuation metrics are heavily influenced by the potential success of REACT in Phase III trials and subsequent regulatory approval.
What are the key factors to evaluate for PROK?
ProKidney Corp. (PROK) holds a MoonshotScore in the low range. Renal Autologous Cell Therapy (REACT) is in Phase III clinical development for diabetic kidney disease, representing a significant potential market opportunity. Not financial advice.
How frequently does PROK data refresh on this page?
PROK's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PROK's recent stock price performance?
ProKidney Corp. (PROK) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Renal Autologous Cell Therapy (REACT) platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PROK overvalued or undervalued right now?
ProKidney Corp. (PROK) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of PROK?
Fractional-share availability for ProKidney Corp. (PROK) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 9 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com